TABLE 2

Summary of the in vivo efavirenz DDI clinical studies used for predictions

PrecipitantPrecipitant Dose (Duration)Dose IntervalEfavirenz Victim Drug Dose (Duration)Efavirenz Dose IntervalObserved DDI (AUCR)Reference
mgmg
Carbamazepine200–400 (21 d)QD600 (35 d)QD0.64Ji et al. (2008)
Ezetimibe10 (11 d)QD400SD0.91Meyer zu Schwabedissen et al. (2012)
10 (24 d)QD400SD1.1Oswald et al. (2012)
Indinavir1200 (7 d)BID600SD0.81Ma et al. (2008)
Itraconazole200 (6 d)QD200SD1.0Jiang et al. (2013)
Nelfinavir1250 (32 wk)BID600 (32 wk)QD0.83Smith et al. (2005)
1250 (7 d)BID600SD0.99Ma et al. (2008)
750 (>4 wk)TID600 (>4 wk)QD1.1Villani et al. (1999)
Nevirapine400 (4 wk)QD600 (6 wk)QD0.71Veldkamp et al. (2001)
Rifampin450 (7 d)QD600SD0.61Yenny et al. (2011)
600 (10 d)QD600SD0.44Cho et al. (2011)
600 (wk)QD600–800 (wk)QD0.63aMatteelli et al. (2007)
10.5 mg/kg (7 d)QD600 (14 d)QD0.78López-Cortés et al. (2002)
600 (8 d)QD600 (8 d)QD0.82Kwara et al. (2011)
Ritonavir100 (7 d)BID600SD1.0Ma et al. (2008)
Saquinavir1600 (7 d)BID600SD0.89Ma et al. (2008)
  • BID, twice daily; CL, clearance; QD, every day; SD, single dose; TID, three times daily.

  • a Observed fold-change in CL (CLcontrol/CLinduced).